PUMA

academical publication management
collect, organize, and share publications

( en | de )

 

Disambiguation of "Wajant, Harald"

Author of the publication

copydeleteadd this publication to your clipboard
Death ligands designed to kill: Development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands

, , and . Results and Problems in Cell Differentiation, (2009)
DOI: 10.1007/400_2008_22

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Univ. -Prof. Dr. -Ing. Harald Garrecht University of Stuttgart

Dr. -Ing. Harald Schönberger University of Stuttgart

Harald Jung University of Stuttgart

Harald Knaus University of Stuttgart

Univ. -Prof. Dr. Harald Gießen University of Stuttgart

 

Other publications of authors with the same name

Therapeutic Targeting of CD95 and the TRAIL Death Receptors, , and . Recent Patents on Anti-Cancer Drug Discovery, 6 (3): 294--310 (2011)Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization, , , , and . FEBS Journal, 275 (9): 2296--2304 (2008)Death ligands designed to kill: Development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands, , and . Results and Problems in Cell Differentiation, (2009)Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface, , , , and . Cancer Immunology, Immunotherapy, 55 (12): 1590--1600 (2006)Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects, , and . BioFactors, 35 (4): 364--372 (2009)A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95, , , , , , , and . Journal of Molecular Medicine, 84 (9): 785--797 (2006)TNFR1-induced activation of the classical NF-κB pathway, and . FEBS Journal, 278 (6): 862--876 (2011)Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor, , , , and . Glia, 62 (2): 272--283 (February 2014)Engineering death receptor ligands for cancer therapy, , and . Cancer Letters, 332 (2): 163--174 (2013)A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death, , , , , and . PLoS ONE, 6 (11): e27621 (2011)